Recruiting

Testing a new drug strategy for returning ovarian cancer after initial treatment

Plain-English translation of NCT05255471 on ClinicalTrials.gov ↗ · Source last updated March 2023 · Translation generated June 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

MITO 35b is testing whether —a targeted cancer medication—can continue to help control ovarian cancer even after it starts progressing again. The study compares this medication to standard platinum-based chemotherapy in women whose cancer has come back after their first treatment with a similar drug. Researchers want to see which approach helps patients live longer and stay healthier.

When ovarian cancer returns after initial treatment, doctors need better options to fight it. This trial exists to see whether continuing with this medication class, even after disease progression, might work better than switching back to traditional chemotherapy.

Do you qualify?

You likely qualify if…

you have high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer that has returned after first-line treatment with a PARP inhibitor
you have had surgery to remove as much cancer as possible after the disease came back
you received at least 6 months of initial PARP inhibitor maintenance therapy without serious side effects or need to permanently reduce your dose
you are 18 years or older with a life expectancy of at least 16 weeks
your blood work and organ function tests are within acceptable ranges, and you are able to take pills by mouth
you have known or are willing to be tested for your BRCA gene status

You likely don't qualify if…

you are pregnant or breastfeeding, or might become pregnant
your blood counts are too low or your liver or kidney function is severely impaired
you received more than one line of platinum-containing chemotherapy before your first PARP inhibitor treatment
you had severe side effects or needed permanent dose reductions from your prior PARP inhibitor that made it unsafe to continue
you cannot provide tumor tissue samples from both your initial and repeat surgeries

What participation looks like

If you join this study, you will be randomly assigned to either continue the medication approach or receive standard chemotherapy. You'll need to start treatment within 3 to 8 weeks after your surgery. You'll take your assigned treatment and have regular check-in visits for blood work and scans to monitor how well the treatment is working and whether you're experiencing any side effects. The study team will track your health and how long the cancer remains controlled.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Testing a new drug strategy for returning ovarian cancer after initial treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)